Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PANK3 | Q9H999 | 7/20 | 0.57 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MLNR | O43193 | 3/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18390266 | 0.84 | MAPT (0.62) | PANK3CNR1KCNJ1KCNH2SMN1; SMN2 | |
| SCHEMBL20962668 | 0.83 | HSD11B1 (0.68) | PANK3CNR1KCNJ1KCNH2SMN1; SMN2 | |
| SCHEMBL7451729 | 0.83 | GPR119 (0.54) | PANK3CNR1KCNJ1KCNH2SMN1; SMN2 | |
| SCHEMBL7502026 | 0.82 | CNR1 (0.58) | PANK3CNR1KCNJ1KCNH2SMN1; SMN2 | |
| SCHEMBL2579137 | 0.82 | SMN1; SMN2 (0.61) | PANK3CNR1KCNJ1KCNH2SMN1; SMN2 | |
| SCHEMBL18390256 | 0.81 | CNR1 (0.57) | PANK3CNR1KCNJ1KCNH2SMN1; SMN2 | |
| SCHEMBL10244601 | 0.81 | GFER (0.59) | SMN1; SMN2HSD11B1MAPTMEN1KMT2A | |
| SCHEMBL19000972 | 0.81 | HSD11B1 (0.65) | SMN1; SMN2HSD11B1MEN1KMT2A | |
| SCHEMBL18705007 | 0.81 | PANK3 (0.57) | PANK3CNR1KCNJ1KCNH2SMN1; SMN2 | |
| SCHEMBL19012366 | 0.78 | FNTA (0.52) | SMN1; SMN2HSD11B1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10023570-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023570-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | PANK3 891/4885CNR1 3994/4885KCNJ1 3789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.